The FDA granted fast track designation to abelacimab for treatment of cancer-associated thrombosis, according to a press release from the agent’s manufacturer.
Abelacimab (Anthos Therapeutics) is a fully human monoclonal antibody that has demonstrated dual inhibitory activity against factor XI and its activated form, factor XIa.
As Healio previously reported, results of a phase 2 study showed a single IV dose of the agent reduced blood clot risk by about 80% compared with daily enoxaparin without increasing bleeding risk after total knee arthroplasty.
“We believe that abelacimab has